Crossmark

Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer

Crossref DOI link: https://doi.org/10.1186/s12885-018-5180-1

Published Online: 2018-12-19

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Conteduca, Vincenza https://orcid.org/0000-0002-6921-714X
Gurioli, Giorgia

Rossi, Lorena

Scarpi, Emanuela

Lolli, Cristian

Schepisi, Giuseppe

Farolfi, Alberto

De Lisi, Delia

Gallà, Valentina

Burgio, Salvatore Luca

Menna, Cecilia

Amadori, Andrea

Losi, Lorena

Amadori, Dino

Costi, Maria Paola

De Giorgi, Ugo
License Information

Text and Data Mining valid from 2018-12-01
More Information

Article History

Received: 14 September 2018

Accepted: 4 December 2018

First Online: 19 December 2018

Ethics approval and consent to participate

: This study was reviewed and approved by the Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS Institutional Review Board Ethics Committee (REC 5485/2018). It was conducted in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki, and all the patients provided written informed consent.

: Not applicable.

: VC and UDG have received speaker honoraria or travel support from Astellas, Janssen-Cilag, Bayer, Ipsen and Sanofi-Aventis. The other authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.